Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Sirtris_Pharmaceuticals> ?p ?o. }
Showing items 1 to 27 of
27
with 100 items per page.
- Sirtris_Pharmaceuticals abstract "Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. Founded in 2004 by Harvard University biologist David Sinclair, venture capitalist Christoph Westphal, and serial entrepreneur Andrew Perlman, the company went public in 2007 and was subsequently purchased by GlaxoSmithKline in 2008 for $720 million. It was operated as a business unit of GSK until 2013, when it was absorbed into GSK, where research and development continues. Sirtris's drug discovery was focused on developing activators of sirtuins, a class of enzyme that may mediate benefits of calorie restriction. The company's current lead candidates are SRT2104 and SRT2379, which are both potent activators of the SIRT1 enzyme. These and related molecules are in clinical development. The company's other drug candidate was SRT-501, a proprietary formulation of the compound resveratrol, possibly an activator of the SIRT1 enzyme. Development of SRT-501 was halted by GlaxoSmithKline in late 2010, due to suspected drug-related adverse effects in study participants. The company later focused on developing more potent synthetic activators of SIRT1 and is investigating SIRT3 as another potential drug target. Studies from rivals Amgen and Pfizer cast doubt on whether SIRT1 was directly activated. Subsequent work provided evidence that the original conclusions of Sinclair were correct: SIRT1 is directly activated by resveratrol and the synthetic activators, with the activator binding in the N-terminus of SIRT1. A mutation in this N-terminal SIRT1 domain (SIRT1-E230K) was shown to block activation by resveratrol and by synthetic activators from Sirtris, both in vitro and in vivo, largely settling the scientific debate. In 2014, SRT1720 and SRT2104 were shown to extend the health span and the lifespan of mice on a standard diet.".
- Sirtris_Pharmaceuticals wikiPageExternalLink www.genocea.com.
- Sirtris_Pharmaceuticals wikiPageExternalLink www.gsk.com.
- Sirtris_Pharmaceuticals wikiPageExternalLink www.ovascience.com.
- Sirtris_Pharmaceuticals wikiPageID "22733563".
- Sirtris_Pharmaceuticals wikiPageRevisionID "600550862".
- Sirtris_Pharmaceuticals hasPhotoCollection Sirtris_Pharmaceuticals.
- Sirtris_Pharmaceuticals subject Category:Biotechnology_companies_of_the_United_States.
- Sirtris_Pharmaceuticals type Abstraction100002137.
- Sirtris_Pharmaceuticals type BiotechnologyCompaniesOfTheUnitedStates.
- Sirtris_Pharmaceuticals type Company108058098.
- Sirtris_Pharmaceuticals type Group100031264.
- Sirtris_Pharmaceuticals type Institution108053576.
- Sirtris_Pharmaceuticals type Organization108008335.
- Sirtris_Pharmaceuticals type SocialGroup107950920.
- Sirtris_Pharmaceuticals type YagoLegalActor.
- Sirtris_Pharmaceuticals type YagoLegalActorGeo.
- Sirtris_Pharmaceuticals type YagoPermanentlyLocatedEntity.
- Sirtris_Pharmaceuticals comment "Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. Founded in 2004 by Harvard University biologist David Sinclair, venture capitalist Christoph Westphal, and serial entrepreneur Andrew Perlman, the company went public in 2007 and was subsequently purchased by GlaxoSmithKline in 2008 for $720 million.".
- Sirtris_Pharmaceuticals label "Sirtris Pharmaceuticals".
- Sirtris_Pharmaceuticals sameAs m.05zk177.
- Sirtris_Pharmaceuticals sameAs Q7530650.
- Sirtris_Pharmaceuticals sameAs Q7530650.
- Sirtris_Pharmaceuticals sameAs Sirtris_Pharmaceuticals.
- Sirtris_Pharmaceuticals wasDerivedFrom Sirtris_Pharmaceuticals?oldid=600550862.
- Sirtris_Pharmaceuticals homepage www.gsk.com.
- Sirtris_Pharmaceuticals isPrimaryTopicOf Sirtris_Pharmaceuticals.